JNJ is in our analyst coverage. Read the full analyst research →

Signal Ledger valuation · JNJ

Johnson & Johnson

What the shares are worth today on our research (management’s own targets for each business): every line valued at the end of FY2030, net debt rolled forward, then discounted back to Sep 27, 2026.

Signal Ledger valuation$226.01−16% vs $267.61
Business value at FY2030
$645B
FY2030 revenue
$126B
FY2030 EPS · P/E
$13.98 · 20×
Discount rate (WACC · equity)
7.49% · 7.87%

Researched Oct 23, 2026 from SEC filing 0000200406-26-000197 · price $267.61 at research time · Valuation methodology

Latest quarter in this research: Q3 2026

Reported Oct 13, 2026 for the quarter to Sep 27, 2026 (company release ↗). This valuation already reflects these results (researched Oct 23, 2026).

Revenue$25.4B
Operating income$65M0.3% margin
Net income$0.21B
Diluted EPS$0.09
SegmentRevenuevs a year agoOperating incomeMargin
Innovative Medicine$16.8B+8%——
MedTech$8.64B+3%——
  • Reported sales rose 5.9%; FY2026 reported sales midpoint raised to 101.2B.
  • Net earnings 210M reflect proposed ovarian-talc settlement and acquisition/collaboration charges; adjusted EPS2.59.
  • Operating income field is a derived EBIT proxy: reported pretax 34M plus net interest expense 31M. JNJ does not present a GAAP operating-income subtotal; segment operating income is therefore null.
  • STELARA biosimilar erosion is offset by oncology, TREMFYA and neuroscience growth; MedTech reported growth 2.5%.

What each business is worth

BusinessModelFY2030 revenueValue todayPer share2030 multipleValue from beyond FY2030
Innovative MedicineMargin$81B$476B$197.5316.2× EBIT67%
MedTechMargin$45B$96B$39.8615.1× EBIT69%
All businesses$126B$571B$237.40

From 2030 back to today

  1. Enterprise value at end of FY2030$645B
  2. Plus net cash at FY2030$32B
  3. Equity value at FY2030$677B
  4. ÷ (1 + 7.87%)^4.3 years at the cost of equity$490B
  5. + dividends paid on the way, discounted$46B

This reconciliation checks the published Signal Ledger valuation against the net-debt path. The difference is 1.4%, inside our 5% tolerance.

From businesses to one share

  1. All businesses, valued today$571B
  2. − borrowings$45B
  3. − finance leases$0B
  4. + cash and short-term investments$17B
  5. ÷ diluted shares2.407B
  6. Signal Ledger valuation$226.01

Year by year to FY2030

Fiscal yearRevenueEBITDACapexFree cash flowNet debt at year end
FY2026$101B$32B$5.2B$22B$25B
FY2027$107B$35B$5.5B$24B$15B
FY2028$113B$38B$5.8B$26B$1.9B
FY2029$119B$41B$6.1B$28B$14B cash
FY2030$126B$44B$6.5B$31B$32B cash

What must be true

  • Innovative Medicine grows revenue from $66.6B in FY2026 to $80.8B in FY2030 (1.2×).
  • MedTech grows revenue from $34.6B in FY2026 to $45.2B in FY2030 (1.3×).
  • Innovative Medicine raises its EBIT margin from 36.9% to 40.9%.
  • MedTech raises its EBIT margin from 12.2% to 16.2%.
  • The company spends $29.1B of capital expenditure through FY2030.
  • Net debt peaks at $27.4B in FY2025 and stays financeable.

What the price implies

To reach $267.61 at our discount rate, Johnson & Johnson would need about $149.8B of FY2030 sales (growth of about 10.3% a year from FY2026) with 32.0% GAAP EBIT margin — versus $126.1B and 32.0% GAAP EBIT margin in our research.

At the research price of $267.61 (2026-10-23), the price asks more than our assumptions overall. These are operating requirements at that price, not additional valuations or forecasts.

If sales and margins changed together

Each row matches the same research price at our unchanged discount rate, by scaling every operating line's margin by one common factor. Sales cover margin and capacity lines only; other valuation lines stay fixed. Margins are revenue-weighted within each metric, before separately modeled corporate costs and eliminations. The conclusion uses the row at our research margins when sales alone can match the price, otherwise the solved row needing the least sales growth; this is a trade-off between growth and profitability, not a forecast.

FY2030 sales factorFY2030 salesFY2026–30 CAGRRequired FY2030 marginRequirement
1.19×At research margins$149.8B10.3%
32.0% GAAP EBIT
Within margin guardrails
1.50×$189.1B16.9%
26.2% GAAP EBIT
Within margin guardrails
2.00×$252.1B25.6%
20.5% GAAP EBIT
Within margin guardrails
3.00×$378.2B39.0%
14.6% GAAP EBIT
Within margin guardrails

CAGR uses $101.2B of same-scope FY2026 sales from the published model or its sourced research base, over four fiscal years. “Within margin guardrails” checks numeric limits only, not commercial plausibility. Each line and year must stay at or below 50.0% GAAP EBIT and 100% EBITDA, or our research margin where that is higher; capacity EBIT uses the engine's equipment depreciation. Unsolved margins are not extrapolated.

Implied discount rate
6.7%

The WACC that makes model value equal the price, shifting WACC and cost of equity by the same amount. Model: 7.5% WACC · 7.9% cost of equity.

All-business FY2030 sales factor
1.19×

FY2030 revenue would need to reach $149.8B (model: $126.1B) across the margin and capacity businesses. FY1 stays fixed; the sales change ramps to FY2030 and stays at that factor thereafter.

If only one business changed

Businesses with margin or capacity revenue paths, ordered by value today. Revenue and margin are separate alternatives; these requirements are not added together.

Innovative Medicine

Revenue alone
FY2030 revenue would need to reach $98B (model: $80.8B).
Margin alone

FY2030 EBIT margin would need to reach 48.9% (model: 40.9%).

MedTech

Revenue alone
FY2030 revenue would need to reach $92.8B (model: $45.2B).
Margin alone

FY2030 EBIT margin would need to reach 30.4% (model: 16.2%).

Mechanical requirements, not forecasts. The separate sales-only and single-business factors are searched from 0.1× to 6×; an unsolved comparison means this business alone cannot get there within those bounds. Single-business revenue changes apply from FY2 onward; margin changes scale the full EBIT or EBITDA margin path. Mixed groups show revenue-weighted EBIT and EBITDA margins separately. Requirements above 100% are not feasible margins. Joint rows instead search non-negative uniform margin factors only up to the EBIT/EBITDA guardrails; the entire margin path scales, including post-FY2030 convergence. Sales and margins change together only in that table. The rate search runs from the largest terminal growth rate plus 0.5 percentage points to 30% WACC.

The discount rate

Cost of equity
7.87%

r_f 3.87% (5-year average 10-year Treasury yield 3.87% (spot 5.13% on 2026-10-21)) + β 0.80 after Blume adjustment × 5%, rounded to 0.01% (1bp)

WACC
7.49%

methodology §4.5: market-weighted WACC, not rounded

10-year Treasury · model / spot
3.87% · 5.13%

The model uses the recorded 5-year average Treasury yield. The spot yield is shown for context.

Every input, with its source

Show 18 inputs · reported, guidance and rule-based
InputValueBasisWhy
Revenue FY2026Innovative Medicine$66.6BRuletarget (methodology §4.2), growth 10.2% jnj.com ↗
Revenue FY2030Innovative Medicine$80.8BGuidancetarget (methodology §4.2), growth 5.0% jnj.com ↗
EBIT margin FY2030Innovative Medicine40.9%Rulelinear path to 40.9% by FY2030 (§4.3 E2: 4.0000 points = 4pp × clamp((CAGR − 1.5%) / 2%, 0, 1); revenue CAGR 6.0% to FY2030; no cited expansion evidence) jnj.com ↗
Maintenance capexInnovative Medicine5.1%ReportedTotal FY2025 PP&E additions 4.832B / revenue 94.193B, including corporate investment, allocated pro rata; exceeds PP&E depreciation. jnj.com ↗
Terminal growthInnovative Medicine2.0%Rulemethodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗
Revenue FY2026MedTech$34.6BReportedtarget (methodology §4.2), growth 2.5% jnj.com ↗
Revenue FY2030MedTech$45.2BGuidancetarget (methodology §4.2), growth 6.9% jnj.com ↗
EBIT margin FY2030MedTech16.2%Rulelinear path to 16.2% by FY2030 (§4.3 E2: 4.0000 points = 4pp × clamp((CAGR − 1.5%) / 2%, 0, 1); revenue CAGR 6.0% to FY2030; no cited expansion evidence) jnj.com ↗
Maintenance capexMedTech5.1%ReportedTotal FY2025 PP&E additions 4.832B / revenue 94.193B, including corporate investment, allocated pro rata; exceeds PP&E depreciation. jnj.com ↗
Terminal growthMedTech2.0%Rulemethodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗
WACCDiscount rates7.49%Rulemethodology §4.5: market-weighted WACC, not rounded FRED DGS10 2021-10-20..2026-10-21
Cost of equityDiscount rates7.87%Ruler_f 3.87% (5-year average 10-year Treasury yield 3.87% (spot 5.13% on 2026-10-21)) + β 0.80 after Blume adjustment × 5%, rounded to 0.01% (1bp) 60 monthly returns vs SPY, 2021-09..2026-09 (adjusted closes)
Tax rateDiscount rates17.3%GuidanceFY2026 effective tax guidance 17.0-17.5%, midpoint; adjusted guidance proxy for future operating taxes, not Q3 litigation-driven GAAP benefit. jnj.com ↗
Cash and short-term investmentsBalance sheet$17.2BReportedcash, cash equivalents and short-term investments us-gaap:CashCashEquivalentsAndShortTermInvestments · 0000200406-26-000197 (filed 2026-10-21)
BorrowingsBalance sheet$44.7BReportedborrowings due within a year plus long-term borrowings us-gaap:ShortTermBorrowings · 0000200406-26-000197 + us-gaap:LongTermDebtNoncurrent · 0000200406-26-000197
Finance leasesBalance sheet$0.0BReportedno finance lease liability reported balance sheet 2026-09-27
SharesBalance sheet2.407BReportedshares outstanding as of 2026-10-15 cover page of 10-Q 0000200406-26-000197
Dividends per yearShareholders$12.7BReportedLast four completed quarters Q4 2025/Q1 2026 at 1.30, Q2/Q3 2026 at 1.34: 5.28; excludes the declared but unpaid Q4 2026 dividend. × 2.407B shares investor.jnj.com ↗

Research notes

  • share-count comparison: 2.4486B quarter 2026-06-29..2026-09-27 · 0000200406-26-000197; point-in-time denominator retained
  • cost of equity 7.87% (β 0.80 after Blume adjustment), WACC 7.5%

Signal Ledger research under one stated scenario — management's targets are delivered — not a forecast that they will be and not investment advice. The research desk (GPT-6.1 (Codex)) gathers filings, guidance and targets; deterministic code applies the samepublished rules to every company and checks the result. Inputs may contain errors; follow the source links before relying on them. Read our valuation methodology →